MEDTRONIC RECEIVES FDA APPROVAL FOR GUARDIAN REAL-TIME CONTINUOUS GLUCOSE MONITORING SYSTEM
Medtronic, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardian(R) REAL-Time System, a doctor-prescribed continuous glucose monitoring (CGM) system for improved diabetes management. Especially well suited for diabetes
patients who frequently monitor their glucose levels, the Guardian REAL-Time System
is intended to help protect patients by alerting users to high and low glucose
levels. The REAL-Time information and retrospective glucose trend data provided
by the Guardian REAL-Time System are designed to help patients more tightly control
glucose levels. Improved glucose control has been shown to significantly reduce
the likelihood of certain long-term complications, including blindness, kidney
failure, amputation, impotence, and heart disease. The system will be available
nationwide by the end of this year.
Business
Wire